Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
380 participants
OBSERVATIONAL
2023-02-09
2024-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The causes of long COVID are still unclear and, accordingly, therapeutic measures are still insufficiently developed. It is assumed that long COVID can in principle affect anyone. Age, gender, obesity and the number of symptoms during an acute COVID-19 illness are discussed as risk factors for long COVID. Another potential risk factor for developing long COVID could be chronic stress, which has been shown to put a strain on the immune system. It is known from infections with other coronaviruses and other viral respiratory diseases that chronic stress can lead to prolonged illness and limited recovery. The aim of this study is to systematically examine chronic stress, as it existed before infection with the coronavirus, as a possible risk factor for long COVID.
For this purpose, 600 people who have been proven to be infected with SARS-CoV-2 and have developed symptoms of COVID-19 will be included in this study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarker Analysis of Stress
NCT00527384
Physiological Response of Cortisol to Cardiac Catheterization
NCT01822847
Cardiovascular Implications of COVID-19
NCT04435457
Anger Expression, Self-focus and Coronary Heart Disease Risk Factors
NCT00005244
The Biomarker and Cardiac Function in Sepsis
NCT00800631
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Hypotheses/research questions/objectives: The primary aim of the study is to analyze the influence of chronic stress on symptom persistence in COVID-19. The study team hypothesizes that elevated levels of pre-existing self-reported chronic stress measured at the beginning of infection predict a higher proportion of patients with symptom persistence at one month after testing positive for SARS-CoV-2 infection (primary outcome). Secondary aims are to investigate the influence of chronic stress on medium- to long-term mental health outcome. In addition, the researchers longitudinally investigate chronic stress, stress-related biomarkers and allostatic load in patients with symptom persistence as compared to recovered patients.
Approach/methods: This is a longitudinal prospective observational study designed according to STROBE guidelines in persons newly tested positive for SARS-CoV-2 infection by qPCR with symptoms of acute COVID-19. Monitoring of COVID-19-related symptoms and symptom persistence is conducted online, by phone and in outpatient clinic visits. Pre-existing chronic stress is investigated by questionnaires on perceived stress and negative life events and by analysis of hair cortisol concentrations prior to infection. Collection of blood allows measurement of SARS-CoV-2 antibodies, stress-related biomarkers and the calculation of allostatic load. Baseline and longitudinal data collection encompasses comorbidities, regular medication, screening for anxiety, depression, acute stress symptoms, and cognitive function.
Level of originality/innovation: This is the first study prospectively investigating chronic stress as a risk factor for long COVID and associated mental health impairment by a multimodal approach. In addition, the researchers probe for stress-related biomarkers associated with symptom persistence and also investigate the impact of protective factors, such as resilience, psychosomatic competence and social support, on symptom persistence. Two novel bio-psycho-social assessment tools contribute to the results of this study. Results of this project will lead to innovative preventive and treatment interventions targeting symptom persistence and mental health sequelae after acute COVID-19.
Primary researchers: Christian Fazekas (PI), Nandu Goswami, Barbara Hanfstingl, Voyko Kavcic.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Klagenfurt
OTHER
Wayne State University
OTHER
Medical University of Graz
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Christian Fazekas
Senior Scientist at Clinical Division of Medical Psychology, Psychosomatics and Psychotherapy, Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical University Graz, Division of Medical Psychology, Psychosomatics and Psychotherapy
Graz, Styria, Austria
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KLI 1100-B
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.